Proxy Votes Now

Home › Activist investors › Tang Capital

Tang Capital

Other large holder. Positions and campaigns from Tang Capital’s SEC filings. Updated November 20, 2026.

Filer entities
TANG CAPITAL MANAGEMENT LLC
SEC CIK
1232621 (TANG CAPITAL MANAGEMENT LLC)
SEC filings
Schedule 13D filings · 13F reports · soliciting material
Latest 13F
Quarter ended Sep 30, 2026, filed Nov 16, 2026: 44 US-listed positions reported; 21 of 1% or more of a company without a 13D are listed below.
25current positions
10new or changed in 90 days; 1 exited
1active campaigns
3campaigns on record

Active campaigns (1)

Nano Dimension Ltd.

Active campaign Public letter or presentation filed · Jun 30, 2026

First 13DJun 30, 2026
Latest filingJun 30, 2026
Filings (2)

Current positions (25)

CompanyStakeSourceFirst disclosedLast changeSince previous filingFlagsStated intent
PMV Pharmaceuticals, Inc. 13.63%7,285,085 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 14, 2026 Nov 14, 2025 Increased Nov 16, 2026 ▲ 5.69 pts Increased 13F: none stated
Boundless Bio, Inc. 12.49%2,840,635 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 5, 2026 Aug 14, 2026 Increased Nov 16, 2026 ▲ 1.23 pts Increased 13F: none stated
Fulcrum Therapeutics, Inc. 9.28%7,080,945 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 23, 2026 Aug 14, 2026 Increased Nov 16, 2026 ▲ 0.73 pts Increased 13F: none stated
Nano Dimension Ltd. 7.9%16,715,812 shares Schedule 13D/A, filed Jul 27, 2026 Jun 30, 2026 Increased Jul 27, 2026 ▲ 1.10 pts Active campaign Seeks changes or engagement
Immunocore Holdings Plc 5.58%2,884,149 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 31, 2026 May 16, 2022 Increased Nov 16, 2026 ▲ 0.44 pts Increased 13F: none stated
AnaptysBio, Inc. 4.93%1,474,262 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Sep 16, 2026 Feb 14, 2020 Increased Nov 16, 2026 ▲ 0.36 pts Increased 13F: none stated
Heron Therapeutics, Inc. 4.73%8,971,427 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 5, 2026 May 15, 2014 Increased Nov 16, 2026 ▲ 1.43 pts Increased 13F: none stated
Tarsus Pharmaceuticals, Inc. 3.89%1,917,666 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 29, 2026 May 16, 2022 Increased Nov 16, 2026 ▲ 0.32 pts Increased 13F: none stated
Compass Pathways PLC 3.67%5,200,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 28, 2026 Feb 14, 2025 Increased Nov 16, 2026 ▲ 0.06 pts Increased 13F: none stated
Ardelyx, Inc. 3.60%9,047,134 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 27, 2026 Nov 16, 2026 — — New 13F: none stated
Celcuity Inc. 2.98%1,464,594 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 29, 2026 Nov 14, 2025 Increased Nov 16, 2026 ▲ 0.29 pts Increased 13F: none stated
Aurinia Pharmaceuticals Inc. 10.0%13,044,106 shares Schedule 13D/A, filed Jun 4, 2026 Sep 12, 2024 Increased Jun 4, 2026 ▲ 0.80 pts — Investment purposes
Compass Therapeutics, Inc. 9.99%17,990,782 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 28, 2026 Nov 14, 2024 — 0.00 pts — 13F: none stated
Pliant Therapeutics, Inc. 9.6%5,859,044 shares Schedule 13D, filed Mar 10, 2025 Mar 10, 2025 — — — Seeks changes or engagement
Galapagos NV 7.5%4,910,525 shares Schedule 13D, filed Feb 14, 2025 Feb 14, 2025 — — — Investment purposes
Nuvectis Pharma, Inc. 5.95%1,577,968 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of May 1, 2026 Aug 14, 2026 — ▲ 0.11 pts — 13F: none stated
Journey Medical Corporation 5.90%1,610,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Mar 31, 2026 Nov 14, 2023 — 0.00 pts — 13F: none stated
Crescent Biopharma, Inc. 3.12%1,160,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 27, 2026 Aug 14, 2025 — 0.00 pts — 13F: none stated
Spyre Therapeutics, Inc. 1.99%1,892,200 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 27, 2026 May 15, 2025 — ▼ 0.15 pts — 13F: none stated
Mirum Pharmaceuticals, Inc. 1.89%1,236,027 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 Aug 15, 2022 — ▼ 0.01 pts — 13F: none stated
PTC Therapeutics, Inc. 1.80%1,500,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 27, 2026 Feb 14, 2024 — 0.00 pts — 13F: none stated
Precigen, Inc. 1.79%6,417,500 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 Nov 14, 2024 — 0.00 pts — 13F: none stated
Viridian Therapeutics, Inc. 1.58%1,792,626 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 Aug 15, 2022 — 0.00 pts — 13F: none stated
LENZ Therapeutics, Inc. 1.44%451,114 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 28, 2026 May 15, 2024 — 0.00 pts — 13F: none stated
Corcept Therapeutics Inc. 1.37%1,500,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 22, 2026 Feb 17, 2026 — ▼ 0.02 pts — 13F: none stated

Stake: the latest 13D’s percent of the class (the largest single reporting person’s, as filed), or for a 13F the reported shares as a percent of the company’s shares outstanding on the date shown. Since previous filing: the change in percentage points against the investor’s previous 13D on the company, or its previous 13F.

Stated intent (13D Item 4)

Item 4 of a Schedule 13D (“Purpose of Transaction”) is where the investor states its plans. The label is a plain reading of that text; the excerpt is quoted from the filing.

Nano Dimension Ltd. · Seeks changes or engagement

“…the Issuer, including, but not limited to, its businesses, operations and prospects. In light of that ongoing evaluation, on June 30, 2026, TCM sent a merger proposal to the Issuer outlining the principal terms on which it would effect a merger between the Issuer and an affiliate of the Reporting Persons (see Exhibit 2). The merger proposal provides that it is subject to limited confirmatory diligence, as well as the execution of a definitive merger…”

Item 4 in the Schedule 13D/A filed Jul 27, 2026; this amendment did not restate Item 4, so the text is from the filing of Jun 30, 2026.

Aurinia Pharmaceuticals Inc. · Investment purposes

“Item 4 of the Original Schedule 13D is hereby amended and restated by replacing the text thereof in its entirety with the following: The Reporting Persons' acquisition was made for investment purposes. In accordance with applicable securities laws, the Reporting Persons may, from time to time and at any time, acquire additional shares and/or other equity, debt or other securities or instruments (collectively, "Securities") of the Issuer in the open market or otherwise, and…”

Item 4 in the Schedule 13D/A filed Jun 4, 2026.

Pliant Therapeutics, Inc. · Seeks changes or engagement

“…its representatives and/or other stockholders, seek to enter into a confidentiality agreement with the Issuer and/or discuss with the Issuer different strategic alternatives or changes to the Issuer's operations. There can be no certainty as to whether discussions with the Issuer will occur, the outcome of any such discussions or whether the Reporting Persons will take any actions relating to the Issuer. Subject to applicable law and regulation, the…”

Item 4 in the Schedule 13D filed Mar 10, 2025.

Galapagos NV · Investment purposes

“The Reporting Persons purchased the Shares and options reported hereunder for investment purposes, and such purchases were made in the Reporting Persons' ordinary course of business. As with their other investments, the Reporting Persons continuously evaluate the Issuer, including, but not limited to, its businesses, operations and prospects. The Reporting Persons may engage…”

Item 4 in the Schedule 13D filed Feb 14, 2025.

Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.

Past campaigns (2)
CompanyOutcome or last statusDateFirst filingHighest stageFilingsMeeting / votes
Jounce Therapeutics, Inc. Settled (agreement with the company) Mar 27, 2023 Mar 27, 2023 — latest (1) —
Aptevo Therapeutics Inc. No campaign filings in the last 12 months Feb 9, 2021 Feb 9, 2021 Soliciting material filed latest (1) —
Past positions (14)
CompanyLast stakeSourceOutcomeDate
Capricor Therapeutics, Inc. 7.05% 13F, quarter ended Jun 30, 2026filed Aug 14, 2026; % of shares outstanding as of Aug 13, 2026 Not in the latest 13F Nov 16, 2026
Kezar Life Sciences, Inc. 0.0% Schedule 13D/A, filed May 13, 2026 Exited May 13, 2026
ESSA Pharma Inc. 9.7% Schedule 13D, filed Nov 8, 2024 Not in the 13F for the quarter ended Sep 30, 2025 Nov 14, 2025
Cargo Therapeutics, Inc. 100.0% Schedule 13D/A, filed Aug 21, 2025 Not in the 13F for the quarter ended Sep 30, 2025 Nov 14, 2025
ITeos Therapeutics, Inc. 100.0% Schedule 13D/A, filed Sep 3, 2025 Not in the 13F for the quarter ended Sep 30, 2025 Nov 14, 2025
HilleVax, Inc. 0.0% Schedule 13D/A, filed Sep 19, 2025 Exited Sep 19, 2025
Allakos Inc. 100.0% Schedule 13D/A, filed May 19, 2025 Not in the 13F for the quarter ended Jun 30, 2025 Aug 14, 2025
Acelyrin, Inc. 0.0% Schedule 13D/A, filed May 23, 2025 Exited May 23, 2025
Singular Genomics Systems, Inc. 14.9% Schedule 13D, filed Sep 18, 2024 Not in the 13F for the quarter ended Mar 31, 2025 May 15, 2025
Reneo Pharmaceuticals, Inc. 10.0% Schedule 13D, filed Dec 26, 2023 Not in the 13F for the quarter ended Dec 31, 2024 Feb 14, 2025
Theseus Pharmaceuticals, Inc. 100.0% Schedule 13D/A, filed Feb 16, 2024 Not in the 13F for the quarter ended Mar 31, 2024 May 15, 2024
LianBio 8.6% Schedule 13D, filed Nov 30, 2023 Not in the 13F for the quarter ended Mar 31, 2024 May 15, 2024
Rain Oncology Inc. 0.0% Schedule 13D/A, filed Feb 2, 2024 Exited Feb 2, 2024
Atea Pharmaceuticals, Inc. 4.8% Schedule 13D/A, filed Nov 28, 2023 Reported below 5% in a 13D/A Nov 28, 2023

How large managers voted in Tang Capital’s proxy contests (meetings since July 2023)

Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.

No proxy contest has gone to a vote since July 1, 2023.

Track record

How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.

1Ongoing
1Settlement
1No outcome in the filings read
Outcome of each campaign (3)
CompanyOutcomeDetailDateFirst filing
Nano Dimension Ltd. Ongoing Public letter or presentation filed Jun 30, 2026 Jun 30, 2026
Jounce Therapeutics, Inc. Settlement agreement with the company Mar 27, 2023 Mar 27, 2023
Aptevo Therapeutics Inc. No outcome in the filings read — Feb 9, 2021 Feb 9, 2021

Share price after the first 13D

The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 1 of 17 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).

CompanyFirst 13DTo latest closeSPY same dates6 months after12 months after
Nano Dimension Ltd. NNDM Jun 30, 2026 -20.7%Jun 30, 2026 – Nov 18, 2026 -2.2% not yet / no price not yet / no price

Prices: daily closes (Nasdaq), as stored by the site.

Other disclosed holders around the same time

Filings by other activists on this list (their first 13D or 13F on the company) and by other holders of 5% or more (Schedule 13D or 13G) dated within 180 days of Tang Capital’s first disclosure in the same company. They are listed together by date only; nothing here says the holders act together.

Ardelyx, Inc. · Tang Capital first disclosed Nov 16, 2026 · 2 other filings
HolderFormDateStake
Millennium Management LLC Schedule 13G Aug 11, 2026 5.7%
Rubric Capital Management LP Schedule 13G Aug 14, 2026 6.6%
Fulcrum Therapeutics, Inc. · Tang Capital first disclosed Aug 14, 2026 · 8 other filings
HolderFormDateStake
RA Capital Management, L.P. Schedule 13G Feb 17, 2026 9.9%
Nantahala Capital Management, LLC Schedule 13G May 15, 2026 4.6%
TCG Crossover GP II, LLC Schedule 13G May 15, 2026 7.9%
EcoR1 Capital, LLC Schedule 13G Jun 25, 2026 9.0%
BlackRock Portfolio Management LLC Schedule 13G Jul 17, 2026 6.0%
BlackRock, Inc. Schedule 13G Jul 28, 2026 7.2%
Bank of America Corp /De/ Schedule 13G Aug 3, 2026 6.7%
Montanova Capital, LLC Schedule 13G Aug 14, 2026 5.5%
Nano Dimension Ltd. · Tang Capital first disclosed Jun 30, 2026 · 2 other filings
HolderFormDateStake
Oramed Pharmaceuticals Inc. Schedule 13D Jan 29, 2026 5.0%
Steel Partners 13F Aug 7, 2026 2.8%
Corcept Therapeutics Inc. · Tang Capital first disclosed Feb 17, 2026 · 2 other filings
HolderFormDateStake
Renaissance Technologies LLC Schedule 13G Feb 12, 2026 5.5%
Ingalls & Snyder LLC Schedule 13G Apr 21, 2026 6.8%
Celcuity Inc. · Tang Capital first disclosed Nov 14, 2025 · 7 other filings
HolderFormDateStake
Baker Bros. Advisors LP Schedule 13D Aug 1, 2025 18.9%
Perceptive Advisors LLC Schedule 13G Aug 4, 2025 6.5%
Lance G. Laing Schedule 13G Nov 13, 2025 3.6%
Brian F. Sullivan Schedule 13G Nov 13, 2025 9.1%
BVF Partners L P/Il Schedule 13G Nov 14, 2025 1.6%
Soleus Capital Management, L.P. Schedule 13G Feb 12, 2026 3.9%
Avoro Capital Advisors LLC Schedule 13G Feb 17, 2026 6.7%
Crescent Biopharma, Inc. · Tang Capital first disclosed Aug 14, 2025 · 1 other filing
HolderFormDateStake
Fairmount Funds Management LLC Schedule 13D Jun 23, 2025 20.0%
ITeos Therapeutics, Inc. · Tang Capital first disclosed Jun 12, 2025 · 1 other filing
HolderFormDateStake
EcoR1 Capital, LLC Schedule 13D May 16, 2025 27.9%
Capricor Therapeutics, Inc. · Tang Capital first disclosed May 15, 2025 · 2 other filings
HolderFormDateStake
The Vanguard Group Schedule 13G Jan 30, 2025 5.0%
BlackRock, Inc. Schedule 13G Feb 5, 2025 6.5%
Spyre Therapeutics, Inc. · Tang Capital first disclosed May 15, 2025 · 5 other filings
HolderFormDateStake
RTW Investments, LP Schedule 13G Feb 14, 2025 6.2%
Perceptive Advisors LLC Schedule 13G Feb 14, 2025 4.4%
Venrock Healthcare Capital Partners III, L.P. Schedule 13G Feb 14, 2025 4.6%
BlackRock, Inc. Schedule 13G Jul 16, 2025 6.6%
The Vanguard Group Schedule 13G Jul 29, 2025 5.1%
Pliant Therapeutics, Inc. · Tang Capital first disclosed Mar 10, 2025 · 8 other filings
HolderFormDateStake
Redmile Group, LLC Schedule 13G Feb 14, 2025 4.8%
FMR LLC Schedule 13G Mar 7, 2025 0.2%
T. Rowe Price Associates, Inc. Schedule 13G May 14, 2025 0.1%
BlackRock, Inc. Schedule 13G Jul 17, 2025 3.4%
The Vanguard Group Schedule 13G Jul 29, 2025 4.9%
Morgan Stanley Schedule 13G Aug 6, 2025 6.1%
Deep Track Capital, LP Schedule 13G Aug 14, 2025 6.4%
Point72 Asset Management, L.P. Schedule 13G Sep 4, 2025 6.7%
Acelyrin, Inc. · Tang Capital first disclosed Feb 20, 2025 · 2 other filings
HolderFormDateStake
Trium Capital LLP Schedule 13D Mar 6, 2025 5.4%
Madison Avenue International LP Schedule 13D Apr 30, 2025 5.1%
Galapagos NV · Tang Capital first disclosed Feb 14, 2025 · 1 other filing
HolderFormDateStake
EcoR1 Capital, LLC Schedule 13D Aug 23, 2024 9.9%
Compass Pathways PLC · Tang Capital first disclosed Feb 14, 2025 · 6 other filings
HolderFormDateStake
Deep Track Capital, LP Schedule 13G Jan 17, 2025 10.0%
Millennium Management LLC Schedule 13G Feb 6, 2025 3.7%
George Jay Goldsmith Schedule 13G Feb 13, 2025 2.6%
Kenneth Griffin Schedule 13G Feb 14, 2025 1.7%
RTW Investments, LP Schedule 13G May 15, 2025 8.3%
Vivo Opportunity Fund Holdings, L.P. Schedule 13G May 15, 2025 6.6%
Precigen, Inc. · Tang Capital first disclosed Nov 14, 2024 · 1 other filing
HolderFormDateStake
Patient Capital Management, LLC Schedule 13G Feb 12, 2025 6.5%
ESSA Pharma Inc. · Tang Capital first disclosed Nov 8, 2024 · 3 other filings
HolderFormDateStake
Biotechnology Value Fund LP Schedule 13D Apr 9, 2025 19.7%
Soleus Capital Master Fund, L.P. Schedule 13D Apr 15, 2025 5.1%
BML Investment Partners, L.P. Schedule 13D Apr 24, 2025 9.5%
Singular Genomics Systems, Inc. · Tang Capital first disclosed Sep 18, 2024 · 2 other filings
HolderFormDateStake
Flynn James E Schedule 13D Sep 12, 2024 6.7%
CRCM LP Schedule 13D Nov 5, 2024 5.6%
Aurinia Pharmaceuticals Inc. · Tang Capital first disclosed Sep 12, 2024 · 1 other filing
HolderFormDateStake
Armistice Capital, LLC Schedule 13G Feb 14, 2025 4.5%
LENZ Therapeutics, Inc. · Tang Capital first disclosed May 15, 2024 · 1 other filing
HolderFormDateStake
Ra Capital Management, L.P. Schedule 13D Mar 28, 2024 0.2%
Atea Pharmaceuticals, Inc. · Tang Capital first disclosed Nov 28, 2023 · 1 other filing
HolderFormDateStake
BML Capital 13F Jul 24, 2023 8.4%

How to read this

Flags (last 90 days)
New first disclosed in the last 90 days. Increased / Decreased shares up or down in a 13D/A or 13F filed in that time. Below 5% a 13D/A reported less than 5%, the reporting threshold. Exited a 13D/A reported no shares, or the investor’s 13F no longer lists a company it listed before.
Active campaign
A contested meeting at which the investor is soliciting proxies is still to be held; or in the last 12 months it filed a proxy-contest document (PREC14A, DEFC14A or DFAN14A soliciting material), stated in a 13D that it nominated directors, filed a letter or presentation to the board or shareholders, or stated public demands in a 13D — and no settlement, withdrawal, contested vote or 13D below 5% is dated on or after the latest such filing. Status is the furthest step since then: Public demands in a 13D < Public letter or soliciting material < Nominations made < Proxy contest filed.
Sources and limits
SEC EDGAR only. 13D data covers filings since June 2023; 13F reports are quarterly and filed up to 45 days after the quarter, and do not show swaps, most options or non-US holdings. Settlements are cooperation agreements disclosed in the company’s 8-K or stated in the investor’s 13D; board seats are read from the 8-K. Text marked Summary of the filing is checked against the filing, whose words are quoted beside it. Nothing on this page predicts what the investor will do.